ASC Private Equity in 2027: Roll-Ups, Multiples and What It Means for Owners
Platforms trade at eleven to seventeen times EBITDA while single surgery centers sell for five to eight. That gap is not random, it rewards margin discipline and operating structure, not just revenue. If a term sheet might be in your future, this episode lays out exactly what buyers price before you ever sit at the table.
Chapters:
0:06 Cold Open
0:27 The Setup
1:49 What the Multiples Actually Reward
2:18 What a Roll-Up Actually Buys, and What It Costs
3:33 Site Neutrality and the Inpatient Only Phase-Out
4:37 What To Actually Do This Quarter
6:13 The Close
Free guide, The 2027 ASC State of the Union: https://sigmatic.ai/guide
Book a free consultation: https://sigmatic.ai/contact
#asc #surgerycenter #ambulatorysurgery #healthcarefinance #orutilization #privateequity #mergersandacquisitions #physicianowned
Chapters
- 00:06 Cold Open
- 00:27 The Setup
- 01:49 What the Multiples Actually Reward
- 02:18 What a Roll-Up Actually Buys, and What It Costs
- 03:33 Site Neutrality and the Inpatient Only Phase-Out
- 04:37 What To Actually Do This Quarter
- 06:13 The Close
Transcript
Read the full transcript Every episode is transcribed, searchable, and quotable. Plain text
Sigmatic: Here's a number that should bother you if you own a surgery center. Right now, multi site platforms are trading at eleven to seventeen times EBITDA. A single center, the kind most of our listeners actually run, sells for five to eight times. That gap is not an accident and it is not random.
Sigmatic: Let's set the table first, because the appetite for ASC capacity did not come out of nowhere. The U S ASC market was about forty-five point three billion dollars in twenty twenty-five, and it is projected to grow at six point one percent a year up to seventy-two point seven billion dollars by twenty thirty-three. There are roughly six thousand four hundred Medicare certified centers operating today, and about sixty-two percent of market revenue sits with physician owned centers. The rest is split across hospital, corporate, and joint venture ownership. Two things are driving the money toward this setting. First, site of service. Medicare, commercial payers, and patients generally pay less for the same procedure in a surgery center than in a hospital outpatient department, and the twenty twenty-six payment rule added five hundred sixty procedures to the ASC covered list, with two hundred seventy-one of those coming straight off the inpatient only list. Second, case migration. Total joints, spine, cardiology, procedures that were inpatient five years ago are routine now in a well run center. Every case that migrates is a case a buyer can build into a model. And it is not just capital paying attention. Search interest in the term surgery center hit its highest point in five years during twenty twenty-six, up about a quarter over the twenty twenty-one to twenty twenty-four average. Attention is moving the same direction as the money.
Sigmatic: Here is the part owners get wrong constantly. Buyers are not pricing your revenue. They are pricing your margin, and the margin gap between a small center and a large one is enormous. EBITDA margin runs twelve point eight percent for centers under three million dollars in revenue, and thirty-seven point three percent for centers over nine million. Think about what that means in practice. A ten center platform running at thirty percent margins is worth more per dollar of EBITDA than a single center running at fifteen percent, because the buyer isn't just buying an asset, they're buying operating discipline. Single specialty centers run five to eight times EBITDA. Multi specialty centers run six to ten times. Multi site platforms run eleven to seventeen times. So here is the blunt read. If you sell a single center at the bottom of its margin range, you are also selling at the bottom of its multiple range. Case costing is not a deal exercise. It is the same number a buyer's diligence team will build whether you hand it to them or not, and it should already be running your decisions long before any term sheet shows up in your inbox.
Sigmatic: Private equity platforms and management companies almost never just buy a center and walk away. The common structure is an equity stake paired with a management fee, and industry convention puts that fee at four percent to seven percent of net revenue. That fee is what funds centralized supply contracting, staffing pools, payer contracting, back office systems, the same scale advantages behind that thirty-seven point three percent margin we just talked about. But it is not free money. Picture a center doing six million dollars in net revenue. At that fee range, you are looking at two hundred forty thousand to four hundred twenty thousand dollars a year coming straight out of distributable margin, regardless of how the equity itself performs. That is real money, every year, whether the deal works out or not. There's also a compliance wrinkle that gets overlooked in the excitement of a term sheet. Physician ownership carries a federal safe harbor requirement, and the practical piece of it is that each physician owner has to perform a meaningful share of their procedures at that center. A platform deal that dilutes a physician below that threshold changes your compliance picture, not just your cap table. We've got more detail on how these management fee structures compare across companies, I'll put the links in the description if you want to dig into that.
Sigmatic: Two Medicare policy threads are quietly reshaping which centers look attractive to a buyer right now. The inpatient only list is being phased out over three years starting in twenty twenty-six, and musculoskeletal procedures go first under the new payment classification. At the same time, site neutral payment policy, which pays the same rate for the same service no matter where it happens, is expanding, and hospital outpatient rates are still generally higher than ASC rates for the same procedure under current policy. As that gap narrows, hospitals have less reason to compete against ASC capacity and more reason to want a piece of it, which is part of why joint ventures are sitting right alongside straight private equity acquisitions as an active deal structure this year. Here's the practical implication. A center whose surgeons already do complex orthopedic and spine cases is a different acquisition target in twenty twenty-seven than it was in twenty twenty-three. Buyers are underwriting the procedures your surgeons can add under the new covered list, not just what's on today's block schedule.
Sigmatic: So what do you do with all of this if you are not selling tomorrow, or even if you might be selling next year. Three things, and none of them require a banker yet. First, build contribution margin by procedure and by payer for your top twenty cases, using actual consumption data, not preference cards that haven't been touched in years. This is the exact number a buyer prices, and it should already be steering your surgeon and payer conversations regardless of any sale. Second, run your center against the core operating benchmarks. Block utilization, first case starts, denial rate, and especially supply cost per case. On that last one, the gap is wide. Centers at the ninetieth percentile run supply cost at thirty-six point eight percent of revenue against a twenty-six point four percent median. That spread is margin, and therefore multiple, sitting on the table unclaimed. Fix the biggest gap before you ever sit down with a buyer or a management company. Third, if a term sheet from a platform or management company is actually in front of you, model that management fee against three years of projected net revenue before you compare multiples side by side, and get independent counsel on the physician ownership safe harbor question before anyone signs anything. One more thing worth knowing if you are planning to open or expand ahead of a sale. Thirty-five states plus the District of Columbia run some form of certificate of need program, and several of them exempt ASCs or apply lighter review, so confirm which rules apply to you before ownership structure changes hands. We've written more on opening or expanding a center with that same pro forma discipline, and on getting your compliance records ready before a buyer's first request list arrives. I'll put the links in the description for anyone working through that right now.
Sigmatic: The spread between a five times multiple and a seventeen times multiple isn't about luck or timing the market perfectly. It's about margin, benchmarks, and whether your numbers would survive a diligence team looking at them with fresh eyes. That work pays off whether a buyer ever shows up or not. If you want to make your A S C more profitable, book a free consultation with us at sigmatic dot A I. We'll go through your own numbers with you and show you exactly where the margin is sitting. The links are in the show notes. Thanks for spending this time with us, and we'll see you next episode.
After the episode
Want a more profitable ASC?
Book a free 30-minute consultation on your own numbers, or leave your email and we will send the 2027 guide first.
Make your ASC more profitable.
A free 30-minute consultation on your own numbers: where the margin is, what to fix first. No obligation.